Please login to the form below
DLBCL
This page shows the latest DLBCL news and features for those working in and with pharma, biotech and healthcare.
ADC Therapeutics pauses enrolment in phase 2 lymphoma study following patient deaths
Zynlonta was being evaluated along with rituximab in unfit or frail patients with DLBCL. ... DLBCL not otherwise specified, DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma.
Latest news
-
Roche's fixed-duration lymphoma treatment approved by European Commission
The authorisation specifically applies to patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least two prior lines of systemic therapy. ... Each year in Europe, an estimated 36, 000 people are diagnosed with
-
Roche's fixed-duration lymphoma treatment granted FDA accelerated approval
The authorisation specifically applies to patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two ... Around 160, 000 people worldwide
-
AbbVie and Genmab’s blood cancer therapy granted FDA accelerated approval
and median duration of response of 15.6 months in heavily pretreated R/R DLBCL patients. ... The FDA approval of Epkinly represents a new treatment mechanism of action for third line DLBCL patients.
-
Janssen signs $245m deal with Cellular Biomedicine for pair of CAR T-cell therapies
DLBCL is the most common type of aggressive lymphoma, accounting for approximately one-third of B-cell lymphomas globally. ... One of CBMG’s therapies, C-CAR039, targets both CD19 and CD20 antigens and is being assessed in a phase 1b study in the US in
-
Kite’s CAR-T therapies recommended by NICE for certain blood cancers
Kite's Yescarta (axicabtagene ciloleucel) has been recommended for adults with diffuse large B‑cell lymphoma (DLBCL) that returns within a year of, or is resistant to, first-line chemoimmunotherapy. ... Dr Sridhar Chaganti, consultant haematologist,
More from news
Approximately 10 fully matching, plus 79 partially matching documents found.
Latest Intelligence
-
European biotech: a new generation of leaders emerges
The phase 2 L-MIND study in diffuse large B-cell lymphoma (DLBCL) showed the combination of tafasitamab with Celgene’s Revlimid (lenalidomide) had an overall response rate of 60%, with
-
Cancer immunotherapy: What's on the horizon?
antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... Celgene and Juno hope to crash the party
-
Deal Watch January 2018
The company switched focus to its JCAR017 programme and recently reported promising data in a pivotal trial for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics portfolio incl
-
Pharma deals in April 2015
its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers.
-
Current development and marketing of biosimilar monoclonal antibodies in Latin America
Argentina. Unknown. Clinical. DLBCL: Ph III planned in Argentina. NA. Biocad. ... NA. BC: Breast cancer; DLBCL: Diffuse large B-cell lymphoma; FL: Follycular Lymphoma; NA: Not applicable; NSCLC: Non-Small Cell Lung Cancer; RA: Rheumatoid Arthritis; TT:
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Subscribe to our email news alerts
- AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study
- ICR and Merck renew strategic alliance for development of new cancer drugs
- DeepMind’s AI tool classifies effects of mutations in genetic diseases
- CDC awards over $23m to Johns Hopkins Center for Health Security project
- Looking to start activity on a currently unpromoted pharmaceutical brand?
- Considering a portfolio review?
No results were found
PMHub
Six Degrees Medical Consulting
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
